دورية
أعرض في EDS

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

التفاصيل البيبلوغرافية
العنوان: Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
المؤلفون: Sands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B, Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Mihaly, Emese, Panaccione, Remo, Scherl, Ellen, Shchukina, Oksana B, Sandborn, William J, Afzali, Anita, Aitova, Lilia, Aldeguer i Mante, Xavier, Allez, Matthieu, Altorjay, István, Argüelles Arias, Federico, Armuzzi, Alessandro, Augustyn, Monika, Bafutto, Mauro, Barrio, Jesus, Begun, Jakob, Behrend, Clint, Bezemer, Geert, Bonnaud, Guillaume, Brankovic, Marija, Byung, Ik Jang, Calvet Calvo, Xavier, Chachu, Karen, Chebli, Julio Maria Fonseca, Cheon, Jae Hee, Cichoz-Lach, Halina, Clark, Larry, Cummings, Fraser, Dalal, Kunal, Danese, Silvio, De Boer, Nanne, De Lourdes Ferrari, Maria, Désilets, Etienne, Dugalic, Predrag, Duvall, George, Fedorishina, Olga, Filip, Rafal, Flores, Cristina, Fogel, Ronald, Fon, James, Frankel, Michael, Friedenberg, Keith, Fries, Walter, Galina, Vassileva, Gietka, Piotr, Goel, Rishi, Hasselblatt, Peter, Herfarth, Hans, Herszényi, László, Hindryckx, Pieter, Hoentjen, Frank, Horjus Talabur Horje, Carmen, Iduru, Satish, Irving, Peter, Isfort, Robert, Jairath, Vipul, Jones, Michael, Kalimullina, Dilara, Katz, Jeffry, Kaur, Manreet, Khurana, Sunil K, Kim, Joo Sung, Kim, Youngho, Kleczkowski, Dariusz, Knezevic, Slavko, Knoll, Aaron, Korman, Louis Y, Kotzev, Iskren, Kulyapin, Andrey, Lee, Kang Moon, Leemreis, Desiree, Leszczyszyn, Jaroslaw, Limdi, Jimmy, Lissauer, Jack, Loftus, Edward, Malecka-Panas, Ewa, Marshall, John, Mihály, Emese, Milan, Lukas, Monteleone, Giovanni, Nagorni, Aleksandar, Owczarek, Danuta, Palekar, Nichole, Panaccione, Remo, Park, Young Soo, Park, Sang Hyoung, Parra, Rogério, Patai, Árpád, Patel, Kamal, Patel, Bhaktasharan, Pershko, Anatoly, Petrova, Elina, Pineton de Chambrun, Guillaume, Randall, Charles, Riestra Menendez, Sabino, Ritter, Timothy, Rivero, Montserrat, Roblin, Xavier, Rocca, Rodolfo, Romatowski, Jacek, Rydzewska, Grazyna, Saibeni, Simone, Salzberg, Bruce, Sarles, Harry, Saunders, John, Savarino, Edoardo Vincenzo, Serclova, Zuzana, Shchukina, Oksana, Siegel, Jonathan, Soofi, Najm, Sparrow, Miles, Stokesberry, David, Suiter, Daniel, Svorcan, Petar, Tkachev, Alexander, Tsonev, Nikolay, Tünde, Kristóf, Ulbrych, Jan, Vanasek, Tomas, Varga, Márta, Vermeire, Severine, Vicente Lidon, Raquel, Weiss, Michael L, Wesley, Emma, Winstead, Nathaniel, Wojcik, Katarzyna, Wypych, Joanna, Zaltman, Cyrla, Zdena, Zadorova
المصدر: The Lancet; June 2022, Vol. 399 Issue: 10342 p2200-2211, 12p
مستخلص: Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease.
قاعدة البيانات: Supplemental Index
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا